Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2019 pubmed 3 citations

NACHT, LRR, and PYD domains-containing Protein 3 and LL-37: prognostic value of new biomarkers in community-acquired pneumonia.

Zhu. Chuanan C; Zhou. Yingfan Y; Zhu. Jiabin J; Liu. Ye Y; Sun. Mengyi M

Key Findings

  • Severe pneumonia patients show significantly increased serum NLRP3 levels.
  • Severe pneumonia patients show significantly decreased serum LL‑37 levels.
  • Higher NLRP3 together with lower LL‑37 is linked to lower 30‑day survival and higher mortality.

Practical Outcomes

  • For biohackers, the study suggests LL‑37 could be a marker of infection severity, but it does not provide a direct way to modify LL‑37 levels or improve outcomes. Until intervention data are available, the main takeaway is that monitoring LL‑37 (e.g., via lab tests) might help gauge how serious a respiratory infection is, though no specific supplementation or protocol is recommended yet.

Summary

In people with community‑acquired pneumonia, those who are sicker have higher blood levels of the inflammation protein NLRP3 and lower levels of the antimicrobial peptide LL‑37. The combination of high NLRP3 and low LL‑37 predicts a worse chance of surviving 30 days.

Abstract

This study aimed to determine the serum levels of NACHT, Leucine-rich repeat (LRR), and Pyrin (PYD) domains-containing Protein 3 (NLRP3) and cathelicidin LL-37, and investigate their prognostic significance in community-acquired pneumonia (CAP). The sample of this prospective study was composed of 76 consecutive patients with CAP. Demographic data and clinical characteristics were collected. Serum levels of NLRP3 and LL-37 were determined by ELISA. Spearman's analysis was used to evaluate the correlation between NLRP3 and LL-37. Association of NLRP3 and LL-37 with 30-day survival and mortality rates was assessed using the Kaplan-Meier curve and logistic regression analysis. Serum NLRP3 significantly increased whereas serum LL-37 significantly decreased in patients with severe CAP. Significant correlation was observed between serum NLRP3 and LL-37 in CAP patients. Patients with higher levels of NLRP3 and lower levels of LL-37 showed lower 30-day survival rate and higher mortality compared with those with lower NLRP3 and higher LL-37 levels. Severe CAP patients tend to present higher serum NLRP3 and lower serum LL-37, which might serve as potential biomarkers for CAP prognosis.

Study Information

Provider

pubmed

Year

2019

Date

2019-08-29T00:00:00.000Z

DOI

10.1590/1806-3713/e20190001

Citations

3

References

30